Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Phuoc T. Tran, Kathryn Lowe, Hao Wang, Hua-Ling Tsai, Daniel Y. Song, Arthur Hung, Jason W.D. Hearn, Tamara L. Lotan, Channing Judith Paller, Mark Christopher Markowski, Samuel R. Denmeade, Michael Anthony Carducci, Mario A. Eisenberger, Matthew Orton, Curtiland Deville, Stanley L. Liauw, Elisabeth I. Heath, Neil B Desai, Tomasz M. Beer, Emmanuel S. Antonarakis
Institutions: University of Maryland, Baltimore, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Oregon Health & Science University, University of Michigan, Indiana University, University of Chicago, Wayne State University, The Barbara Ann Karmanos Cancer Institute, The University of Texas Southwestern Medical Center, OHSU Knight Cancer Institute, Masonic Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286293783